Reuters logo
3 个月内
BRIEF-Tonix Pharmaceuticals reports results from the FDA initial cross-disciplinary breakthrough meeting on TNX-102 SL for posttraumatic stress disorder
2017年4月11日 / 中午11点32分 / 3 个月内

BRIEF-Tonix Pharmaceuticals reports results from the FDA initial cross-disciplinary breakthrough meeting on TNX-102 SL for posttraumatic stress disorder

1 分钟阅读

April 11 (Reuters) - Tonix Pharmaceuticals Holding Corp

* Tonix Pharmaceuticals reports results from U.S. FDA initial cross-disciplinary breakthrough meeting on TNX-102 SL for posttraumatic stress disorder

* Tonix Pharmaceuticals - FDA confirmed single-study NDA approval could be possible based on statistically persuasive topline data from ongoing Honor Study

* Tonix Pharmaceuticals - FDA agreed studies in assessing abuse potential of TNX-102 SL are not required to support TNX-102 SL NDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below